Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and
mortality in heart transplant recipients as the second most frequent cause of all deaths at 3
years. In distinction from general coronary atherosclerosis, CAV affects diffusely the entire
coronary vasculature with marked intimal proliferation and concentric vascular thickening and
fibrosis. It was demonstrated that most of the intimal thickening due to CAV occurs during
the first year after transplantation. Furthermore, the severity of the CAV appears to
correlate with lipid abnormalities and elevated low-density lipoprotein cholesterol (LDL-C)
is very common after transplantation with nadir of LDL levels occurring at 6 months.
Because of drug-drug interactions, heart transplant recipients cannot be treated with
adequate doses of statins to achieve desirable reduction of LDL-C levels (reduction ˂ 60% of
LDL-C). The use of alternative lipid-lowering drugs including bile acid sequestrates,
fibrates, nicotinic acid or ezetimibe is not recommended in post-transplant scenario.
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) increase availability has
emerged as a novel drug tool for LDL-C lowering, capable to lower LDL-C by more than 60% even
in statin-treated patients with very good safety profile.
Although heart transplant recipients fulfill approved indication and standard clinical
guidelines of a PCSK9 inhibitor, alirocumab, there are no available data on use of PCSK9
inhibitor in post-transplant situation.
The purpose of the ACAV study is to clarify efficacy and safety of alirocumab compared to
placebo administered during the first year after transplantation in heart transplant
recipients in addition to background atorvastatin therapy. Except lipid profile, optical
coherence tomography (OCT) will be performed as the objective efficacy endpoint to examine
thickness and lumen of coronary vessels. It is expected that inhibition of PCSK9 in heart
transplant recipient will dramatically improve post-transplant lipoprotein levels and perhaps
slow down development of CAV in the most critical period of the first year after
transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Institute for Clinical and Experimental Medicine
Collaborators:
Centre of Cardiovascular and Transplantation Surgery, Czech Republic St. Anne's University Hospital Brno, Czech Republic